A MULTI-COHORT, RANDOMIZED, PHASE 2, OPEN-LABEL STUDY TO ASSESS THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF BIVV020 FOR PREVENTION AND TREATMENT OF ANTIBODY-MEDIATED REJECTION IN ADULT KIDNEY TRANSPLANT RECIPIENTS

Registry ID

ACT17012

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Start date

2023-09-28

Last update

2021-09-17

Conditions

• KIDNEY TRANSPLANTATION

Related clinical trials

• A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN RECIPIENTS OF KIDNEY TRANSPLANTS WITH LATE ISOLATED MICROVASCULAR INFLAMMATION (MVI) - (TRANSPIRE0
• A PHASE 2B, NON-RANDOMIZED, CONTROLLED, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE PERSISTENCE OF IMMUNE RESPONSE OF THE ADJUVANTED RSVPREF3 VACCINE AND THE SAFETY AND IMMUNOGENICITY FOLLOWING REVACCINATION IN LUNG AND KIDNEY TRANSPLANT RECIPIENTS (¿18 YEARS OF AGE)
• SEMAGLUTIDE FOR THE PREVENTION OF POST-TRANSPLANT DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RAVULIZUMAB ADMINISTERED INTRAVENOUSLY IN ADULT PARTICIPANTS AT HIGH RISK OF DELAYED GRAFT FUNCTION AFTER KIDNEY TRANSPLANTATION
• EVALUATION OF THIOSULFATE IN END STAGE RENAL DISEASE AND KIDNEY TRANSPLANTATION
• A PHASE 2B, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS (¿50 YEARS OF AGE) WHEN ADMINISTERED TO LUNG AND RENAL TRANSPLANT RECIPIENTS COMPARING 1 VERSUS 2 DOSES AND COMPARED TO HEALTHY CONTROLS (¿50 YEARS OF AGE) RECEIVING 1 DOSE

View on source registry